JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M112247200 on February 19, 2002

J. Biol. Chem., Vol. 277, Issue 18, 15413-15418, May 3, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/18/15413    most recent
M112247200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kärkkäinen, M.
Right arrow Articles by Ehnholm, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kärkkäinen, M.
Right arrow Articles by Ehnholm, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Isolation and Partial Characterization of the Inactive and Active Forms of Human Plasma Phospholipid Transfer Protein (PLTP)*

Minna KärkkäinenDagger , Tomoichiro Oka§, Vesa M. OlkkonenDagger , Jari MetsoDagger , Hiroaki Hattori§, Matti JauhiainenDagger , and Christian EhnholmDagger

From the Dagger  Department of Molecular Medicine, National Public Health Institute, Biomedicum, P. O. Box 104, Helsinki FIN-00251, Finland and § Research Division, Research and Development Center, BML Inc., 1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan

Plasma phospholipid transfer protein (PLTP) plays an important role in lipoprotein metabolism. Two forms of PLTP exist in human plasma, one catalytically active (high activity form, HA-PLTP) and the other inactive (low activity form, LA-PLTP) (Oka, T., Kujiraoka, T., Ito, M., Egashira, T., Takahashi, S., Nanjee, N. M., Miller, N. E., Metso, J., Olkkonen, V. M., Ehnholm, C., Jauhiainen, M., and Hattori, H. (2000) J. Lipid Res. 41, 1651-1657). The two forms are associated with macromolecular complexes of different size. The apparent size of LA-PLTP is 520 kDa and that of HA-PLTP is 160 kDa. Of the circulating PLTP mass only a minor portion is in the HA-PLTP form in normolipidemic subjects. In the present study we have isolated and partially characterized the LA and HA forms of PLTP. Both LA- and HA-PLTP bind to heparin-Sepharose and can be separated by elution with 0-0.5 M NaCl gradient, with HA-PLTP displaying higher affinity for the matrix. LA-PLTP was further purified using hydrophobic butyl-Sepharose and anti-PLTP immunoaffinity chromatography steps. HA-PLTP was subjected to a second heparin-Sepharose step and hydroxylapatite chromatography. Analysis of the two forms of PLTP by SDS-PAGE, Western blotting, immunoprecipitation, and gel filtration demonstrates that LA-PLTP is complexed with apoA-I whereas HA-PLTP is not. Instead, HA-PLTP copurified with apoE. Based on these findings we suggest a model in which nascent PLTP enters the circulation as a high specific activity form not associated with apoA-I. During or after the transfer of lipolytic surface remnants to HDL, PLTP is transferred to apoA-I-containing HDL particles and thereby becomes part of the low activity complex.

* This work was supported by the International HDL Research Awards Program (to C. E., M. J., V. M. O.), Finnish Foundation for Cardiovascular Research (to M. K. and M. J.), the Wihuri Research Foundation (to M. K.), and the Sigrid Juselius Foundation (to V. M. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: National Public Health Institute, Dept. of Molecular Medicine, P. O. Box 104 (Haartmaninkatu 8), Helsinki FIN-00251, Finland. Tel. 358-9-4744-8258; Fax: 358-9-4744-8960; E-mail: Christian.Ehnholm@ktl.fi.

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
N. Settasatian, P. J. Barter, and K.-A. Rye
Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein
J. Lipid Res., January 1, 2008; 49(1): 115 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. Vikstedt, D. Ye, J. Metso, R. B. Hildebrand, T. J.C. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck
Macrophage Phospholipid Transfer Protein Contributes Significantly to Total Plasma Phospholipid Transfer Activity and Its Deficiency Leads to Diminished Atherosclerotic Lesion Development
Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 578 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang
Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 190 - 196.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. C. Cheung and J. J. Albers
Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins
J. Lipid Res., June 1, 2006; 47(6): 1315 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention (
Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e?
Diabetes, May 1, 2006; 55(5): 1491 - 1496.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al.
Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample
J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. Siggins, M. Karkkainen, J. Tenhunen, J. Metso, E. Tahvanainen, V. M. Olkkonen, M. Jauhiainen, and C. Ehnholm
Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA
J. Lipid Res., February 1, 2004; 45(2): 387 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Schlitt, C. Bickel, P. Thumma, S. Blankenberg, H. J. Rupprecht, J. Meyer, and X.-C. Jiang
High Plasma Phospholipid Transfer Protein Levels as a Risk Factor for Coronary Artery Disease
Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1857 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. Siggins, M. Jauhiainen, V. M. Olkkonen, J. Tenhunen, and C. Ehnholm
PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma
J. Lipid Res., September 1, 2003; 44(9): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Kujiraoka, M. N. Nanjee, T. Oka, M. Ito, M. Nagano, C. J. Cooke, S. Takahashi, W. L. Olszewski, J. S. Wong, I. P. Stepanova, et al.
Effects of Intravenous Apolipoprotein A-I/Phosphatidylcholine Discs on LCAT, PLTP, and CETP in Plasma and Peripheral Lymph in Humans
Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1653 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
I. J. A. M. Jonkers, A. H. M. Smelt, H. Hattori, L. M. Scheek, T. van Gent, F. H. A. F. de Man, A. van der Laarse, and A. van Tol
Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy
J. Lipid Res., August 1, 2003; 44(8): 1462 - 1469.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. D. O'Brien, S. Vuletic, T. O. McDonald, G. Wolfbauer, K. Lewis, A.-Y. Tu, S. Marcovina, T. N. Wight, A. Chait, and J. J. Albers
Cell-Associated and Extracellular Phospholipid Transfer Protein in Human Coronary Atherosclerosis
Circulation, July 22, 2003; 108(3): 270 - 274.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Lee, J. Metso, M. Jauhiainen, and P. T. Kovanen
Degradation of Phospholipid Transfer Protein (PLTP) and PLTP-generated Pre-beta -high Density Lipoprotein by Mast Cell Chymase Impairs High Affinity Efflux of Cholesterol from Macrophage Foam Cells
J. Biol. Chem., April 4, 2003; 278(15): 13539 - 13545.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, I. Lankhuizen, and A. van Tol
Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion
J. Lipid Res., November 1, 2002; 43(11): 1875 - 1880.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
T. Oka, S. Yamashita, T. Kujiraoka, M. Ito, M. Nagano, Y. Sagehashi, T. Egashira, M. N. Nanjee, K.-i. Hirano, N. E. Miller, et al.
Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia
J. Lipid Res., August 1, 2002; 43(8): 1236 - 1243.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.